THRIVE is a competitive seed grant program designed to support research that helps to predict, reduce, or prevent adverse events associated with life-saving cancer therapy. We are pleased to announce this year’s grant award winners, selected from a large pool of highly competitive proposals received from research around the globe. Each awardee , listed below, will receive $50,000 in funding to support their research in making cancer patient quality of life an active research priority.
2023 THRIVE Grant Award Winners
HESI THRIVE Research Study: Circulating Biomarkers of Anthracycline Cardiac Toxicity in Patients with Lymphoma
- Dr. Aarti Asnani, MD
- Section Head, Cardio-Oncology | Director, Cardiology Grand Rounds
- Associate Program Director for Resident Research, Department of Medicine, Beth Israel Deaconess Medical Center
- Assistant Professor, Harvard Medical School
HESI THRIVE Research Study: Investigating epigenetic changes in methotrexate-induced cognitive impairment
- Dr. Jeremy Willekens, PhD
- Postdoc Fellow, Rutgers Biomedical and Health Sciences
- Division of Hematology/Oncology
HESI THRIVE Research Study: Biomarkers to Inform Kidney Toxicities from Immune Checkpoint Inhibitors
- Dr. Melanie S. Joy, PharmD, PhD, FCCP, FASN
- Professor, Director of Innovation and Commercialization, Skaggs School of Pharmacy and Pharmaceutical Sciences
- SPARK/REACH Program, Director of Entrepreneurship Education
- University of Colorado, Anschutz Medical Campus
By providing researchers with both seed funding and access to critical networks, THRIVE will enhance the visibility of the patient need, the value of the research, and the reasons that larger funding entities might elect to incorporate these research streams into future funding priorities. Click here to learn more about grant guidelines, the application process, and selection process.